Waters Corporation (WAT)

The methods disagree: one places the value today above the price ($432) and the other below.

Today — expensive, no margin of safety: at $432 trades ~19.7% above its value discounted to today (~$361); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Preserva valor: the target price ($450) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$224.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($432) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The implied growth (6.5%/year) is in line with our base case (6.5%/year) → the price is consistent with the projection.

That growth implies ~$2 bn of owner earnings in year 5 (vs ~$2 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). Cash accumulates the retained surplus —what is not returned as dividend or buyback—, so that EV falls and multiples compress going forward. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

A sum-of-the-parts model. Year 0 is the TTM to 4-Jul-2026 ($4.644bn of revenue, $0.330bn of GAAP operating income), which includes only ~5 months of contribution from Biosciences & Diagnostic Solutions (BDS, acquired from Becton Dickinson on 9-Feb-2026 for US$16.8bn in a Reverse Morris Trust transaction) and is heavily depressed by non-recurring transaction costs: in the second quarter of 2026 alone, US$155M of fair value step-ups on inventory/assets, US$244M of acquired intangible amortization and US$49M of restructuring. Reported TTM net income ($0.167bn) and the TTM operating margin (7.1%) are not representative of the business in steady state. Year +1y anchors to the company's guidance in the 8-K of 4-Aug-2026 (raised after the second quarter): total FY2026 revenue of US$6.415-6.476bn (midpoint US$6.4455bn, with organic revenue of US$3.370-3.431bn plus acquired business revenue of ~US$3.045bn on an owned-period basis) and adjusted earnings per share of US$14.45-14.65 (midpoint US$14.55, +10-12% year over year), which excludes the integration costs cited. The implied adjusted net margin for +1y is approximately 22.2% and the adjusted operating margin approximately 29% (consistent with the 25.0% already reported in the second quarter of 2026, with expected improvement from cost synergies of ~US$200M over three years and favorable year-end seasonality). From +2y a full twelve-month annualization of BDS is assumed (the FY2026 guidance midpoint captures only ~89% of the year because of the closing date) and a smooth deceleration of legacy organic growth (7-9% in constant currency today, toward 4.5% at +5y) and of the acquired business (which reported 4% comparable-basis growth in the second quarter of 2026, accelerating from a 180-day revitalization toward mid-single-digit growth). Sum of the parts: the company reorganized post-acquisition into four divisions (Analytical Sciences, Biosciences, Advanced Diagnostics, Materials Sciences) of different economic natures -high-margin scientific instrumentation with an R&D/quality control sales cycle, versus in vitro clinical diagnostics with reimbursement dynamics and a regulated sales cycle-, and the company itself declares that it is still assessing how it will report its segments in the future. It is valued at the enterprise level, on a multiple of after-tax operating income: the metric is pre-interest, so the debt taken on to fund the acquisition is subtracted once, in the bridge, and not again inside earnings. It is modeled as two pieces: (1) the legacy Waters+TA instruments business (Analytical Sciences and Materials Sciences), with a wider moat and a multiple toward the ceiling of the medical instrumentation band; (2) Biosciences & Advanced Diagnostics (BDS), with a multiple toward the floor of the same band for integration risk, the leverage assumed to fund the acquisition and the lack of its own track record under Waters. Consolidated margins are a single assumption (there is no breakdown of operating income by division in the filing) declared explicitly as an approximation; the split between pieces is done by projected revenue share at year 5, which comes from annualizing the acquired business's revenue guidance and the legacy's guided organic growth. D&A and capex stay elevated in the path from the non-cash amortization of the intangibles acquired in the transaction (net intangible assets of US$8,521M after the purchase, against US$558M before).

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (EV falls as cash increases). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $450 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $432, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $450 in 5 years and a required return of 4.5% annually, the maximum to pay today is $361. Against the current market price ($432), the margin of safety is -19.7% (trades above the maximum → a premium is paid) and the total return at that price would be 0.8% annually.

• Rich entry multiple. The price already demands sustained integration execution
• No market discount. No signs of a market-perception discount
• Disciplined exit multiple. The model uses an exit multiple within the historical medical instrumentation band, not the rich entry multiple
• No dividend cushioning returns. With no dividend payment, shareholder return depends entirely on price appreciation and multiple compression or expansion

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✕ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (234%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Margins depressed by integration. GAAP TTM operating margin (7.1%) reflects non-recurring acquisition costs, not the real economics of the business in steady state (~25-29% adjusted)
• Distorted cash conversion. TTM operating cash flow is affected by one-time transition-related cash movements (transition services agreement, escrow asset)
• Low SBC. Stock-based compensation is just 1.6% of TTM revenue, with no material dilution trap in the valuation metric
• High non-cash D&A. Amortization of acquired intangibles from the BDS transaction sharply raises reported D&A without proportionally consuming cash

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The central driver of the legacy business is the installed instrument base multiplied by the consumables repurchase rate and service-contract penetration: each instrument sold generates a stream of recurring consumables and service revenue over its useful life, which in 2025 accounted for more than 35% of the Waters division's sales. The acquired diagnostics and biosciences business monetizes similarly -recurring instruments and reagents- but on a base of hospital and clinical laboratory customers with regulated, reimbursement-dependent sales cycles, distinct from the legacy business's pharmaceutical R&D customer base.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (04-jul-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• FY2026 guidance raised. Revenue and adjusted earnings per share guidance raised after a second quarter that beat expectations across all four divisions
• Acceleration of the acquired business. BDS moved to mid-single-digit growth under a 180-day revitalization plan, faster than expected at the time of closing
• End-market recovery. Low double-digit growth in pharmaceutical and academic/government in constant currency, in a recovery in demand
• Year-1 growth distorted. The jump in revenue from TTM to +1a mostly reflects the annualization of the BDS acquisition, not organic growth alone

• High recurring revenue. More than 35% of the legacy Waters business's sales come from contracted service, plus periodic-repurchase consumables
• Diversified customer base. No single customer exceeded 2% of net sales in 2023-2025
• Mixed nature post-acquisition. The business combines R&D instrumentation with regulated clinical diagnostics, two distinct customer and reimbursement dynamics still being integrated
• China exposure. Sales fell 10% in 2024 on trade tensions and local competition before recovering 10% in 2025, with persistent tariff uncertainty

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✕Interest coverage (EBIT / interest)2.8x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 234% of ROIC
• ✕Value creation (ROIC − 10% bar)-3pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.3x — no over-investment
• !Float / working capitalConsumes cash $0.2 bn (positive WC)
• !Dilution (SBC % of revenue + shares)SBC 1.6% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Elevated debt from the acquisition. Total debt rose from ~$1.4bn to ~$5.1bn after assuming ~$4.0bn of new debt to fund the BDS acquisition
• Moderate cash. $539M of cash as of Jul-4-2026, against a much more leveraged balance sheet than before the acquisition
• Equity expanded by the transaction. Equity rose to $15.2bn (from $2.6bn) from the acquisition's accounting, including $9.4bn of goodwill
• Deleveraging priority. The company will foreseeably prioritize debt repayment over buybacks or dividends in the near to medium term

Who owns the shares — the alignment and whether there is a controlling shareholder.

• No concentrated control. Directors and executives as a group hold barely ~0.3% of shares; institutional ownership is dispersed (BlackRock ~5.5%, Fundsmith ~5.0%)
• Transformational acquisition executed. Successful closing of the BDS acquisition on the committed timeline, with a guidance beat in the first full quarter under Waters
• Buybacks nearly nil. No open-market buybacks in 2024 or 2025, prioritizing post-acquisition deleveraging over capital return
• No dividend. The company does not declare or pay dividends in the periods covered by the filings analyzed

• There is no clear identifiable source of discount: the price already reflects a guidance raise
• The second-quarter 2026 release beat expectations across all four divisions, which already pushed the price higher rather than leaving it lagging
• There is no evidence of motivated sellers or a restructuring obscuring value: the business is reporting growth and raised guidance, not a situation of temporary discredit

Unlike a classic perception-driven discount opportunity, WAT shows no signs of missing buyers or motivated sellers: it beat its own guidance. The market is already paying for sustained execution of the BDS integration and full capture of the projected synergies. The method finds no source of discount because there isn't one: the Preserves value reflects that the entry price is rich against a disciplined exit multiple, not a market anomaly favoring the buyer.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -7%/year (-29% total): the margin of safety protects the downside. The bull (+6%/year, +36% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• BDS integration. Risk of failing to capture the projected cost and revenue synergies or of delays integrating personnel, systems and internal controls
• Leverage. ~$4.0bn of new debt assumed for the acquisition limits financial flexibility against operational surprises
• Demanding valuation. The current price already capitalizes near-flawless execution, leaving little margin for error against disappointments
• China exposure. Historical volatility in China sales from trade tensions and local competition, with ongoing tariff uncertainty
• Larger-scale competition. More diversified, better-resourced rivals in instrumentation (Agilent, Danaher, Thermo Fisher) and in diagnostics (Danaher, Revvity, Cytek, bioMérieux)

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: ROIC 7% does not clear the 10% bar.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 7% at a multiple/growth of 25.8 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 1% (EBIT/EV) + ROIC 7% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 6%, in line with our 7%: perception and reality aligned.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -7%/yr, bull-scenario ceiling +6%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, stable; sources: intangibles, switching costs, cost advantage, efficient scale → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting 6%, within what we project (7%) — the story squares with the numbers.